Neighborhood Socioeconomic Status and Adverse Outcomes in Patients with Cardiovascular Disease
Topel ML, Kim JH, Mujahid MS
Am J Cardiol. 2019;23(2):284-90
Leggi
Association Between Intake of Non-Sugar Sweeteners and Health Outcomes: Systematic Review and Meta-Analyses of Randomised and Non-Randomised Controlled Trials and Observational Studies
Toews I, Lohner S, Küllenberg de Gaudry D, et al.
BMJ. 2019;364:k4718
Leggi
Are Newer Insulin Analogues Better for People With Type 1 Diabetes?
Misra S, Mathieu C
Diabetic Medicine. Pub. online 26 December 2018
Leggi
Significance of obstetrical history with future cardiovascular disease risk
Bassily E, Bell C, Verma S, et al.
The American Journal of Medicine. Published online, 11 December 2018
Leggi
(Over)eating out at major UK restaurant chains: observational study of energy content of main meals
Robinson E, Jones A, Whitelock V, et al.
BMJ 2018;363 :k498
Leggi
2018 ACC expert consensus decision pathway on novel therapies for cardiovascular risk reduction in patients with type 2 diabetes and atherosclerotic cardiovascular disease – A report of the American College of Cardiology task force on expert consensus decision pathways
Das SR, Everett BM, Birtcher KK, et al.
J Am Coll Cardiol. 2018;72(24):3200-23
Leggi
Body mass index, change in weight, body weight variability and outcomes in type II diabetes mellitus (from the ACCORD trial)
Yeboah P, Hsu FC, Bertoni AG, Yeboah J
American Journal of Cardiology. Published online, 3 December 2018
Leggi
The association of polyunsaturated fatty acid δ-5-desaturase activity with risk factors for type 2 diabetes is dependent on plasma apob-lipoproteins in overweight and obese adults
Lamantia V, Bissonnette S, Provost V, et al.
J Nutr. Published online, 10 December 2018
Leggi
Glycated hemoglobin and outcomes of heart failure (get-with-the-guidelines–heart failure)
Echouffo-Tcheugui JB, Sheng S, DeVore AD, et al.
American Journal of Cardiology. Published online, 3 December 2018
Leggi
Annali AMD 2018 – Diabete, obesità e malattia cardiovascolare
La disponibilità negli ultimi anni di nuovi farmaci innovativi appartenenti alla classe degli inibitori del co-trasportatore di sodio glucosio 2 (SGLT2i) e degli agonisti recettoriali del glucagon-like peptide (GLP-1 RA) ha dimostrato evidenti benefici cardiovascolari nei pazienti affetti da diabete, con una conseguente riduzione dell’impatto clinico, sociale ed economico delle…
Leggi